Evaluation of PFOA and PFOS for human health standards

- Sarah Yang, Ph.D.
- Groundwater Toxicologist

Meghan Williams, M.S. Environmental Toxicologist






Today's presentation

- Basis for human health standards Groundwater standard process
- Recommended groundwater standard for PFOA
- **Recommended groundwater standard for PFOS**

Standards are set to protect health of Wisconsin residents.



Most human health standards are based on toxicology studies conducted in research animals.














Dose response experiments are used to figure out **how much** of a chemical is needed to cause an effect.




Most effects have a threshold.


There is some level below which these effects are not expected to occur








Cancer effects are usually considered to not have a threshold.




Any level can increase the cancer risk.



Most human health standards are based on toxicology studies conducted in research animals.



Toxicology studies called dose response experiments are used to figure out **how much** of a chemical is needed to cause an effect.




NOAEL LOAEL Cancer slope factor


Toxicology data are used to set standards that protect health of Wisconsin residents.

Groundwater



Two-thirds of Wisconsin residents use groundwater.






Groundwater standard process



The enforcement standard is established from available health information.







Federal number





Technical information



Cancer risk



Concentration of a chemical in drinking water that is established by the EPA. Maximum contaminant level (MCL)



Maximum contaminant level (MCL) The highest level of a contaminant that is allowed in drinking water.



Maximum contaminant level (MCL) is the highest level of a contaminant that is allowed in drinking water.

Maximum contaminant level goal (MCLG) The level of a contaminant in drinking water below which there is no known or expected risk to human health.





Maximum contaminant level (MCL)

is set as close to

Maximum contaminant level goal (MCLG)


as feasible.





MCLG

All other substances







Concentration of a chemical in drinking water that is established by the EPA.

Maximum contaminant level (MCL)

Health advisory


Health advisory Level at which health effects are not anticipated to occur over a specified duration







Concentration of a chemical in drinking water that is established by the EPA. Maximum contaminant level (MCL) Health advisory **Concentration based on** cancer risk level





Concentration of a chemical in drinking water that is established by the DNR. Maximum contaminant level in Wis. Admin Code


NR 809




Amount of a chemical a person can be exposed to every day without health effects.

Oral reference dose

Acceptable daily intake (ADI)






Enforcement standards can be based on:



DHS can establish an ADI from available scientific information when: There is no federal number or EPA value.

The information was not considered when the federal number/EPA value was established.




Enforcement standards can be based on:



DHS must ensure the standard does not allow for unacceptable cancer risk.

More than 1 case in 1,000,000 people

When an enforcement standard is based on:




When an enforcement standard is based on:



EPA value



Technical information





Calculate the appropriate standard






Enforcement standards based on









Enforcement standards based on




Set to protect from a lifetime of exposure





The preventive action limit is set at a percentage of the enforcement standard.







Substances that cause carcinogenic, mutagenic, teratogenic, or interactive effects



PFOA

Perfluorooctanoic acid





Technical information

Cancer risk



Lifetime health advisory 70 ng/L for PFOA and PFOS Established in 2016



Concentration based on cancer risk

500 ng/L for PFOA

1 in 1,000,000 risk

Established in 2016



Oral reference dose 20 ng/kg-d Established for use in setting the lifetime health advisory

ATSDR = Agency for Toxic Substances and Disease Registry

Available scientific information for **PFOA:**



Intermediate minimum risk level (MRL) 3 ng/kg-d Proposed by ATSDR in 2018 Exposure duration of 15 – 365 days



Critical studies

Toxicity studies

Modeling studies



Cancer slope factor $0.07 (mg/kg-d)^{-1}$ Established by EPA to set the concentration based on cancer risk





State drinking water standard






Technical information




Cancer risk


In 2016, EPA established a combined health advisory of 70 ng/L for PFOA and PFOS.

Most common endpoints:






Development and reproduction are the most sensitive effects.





Babies are most sensitive to the effects of PFOA.








Study selected was Lau et al., 2006













We do not know how much PFAS has to be in our blood to cause health effects.






EPA's approach



PFOA level in pregnant woman's blood

PFOA?

PFOA level in mother rat's blood at the dose that caused the critical effect in offspring 80




EPA's approach

Estimate how much PFOA was in - animal's blood at the dose that caused the critical effect





(C.S.


PFOA



EPA's approach







We have learned more about PFOA since 2016.




PFOA can cross the placenta during pregnancy.


PFOA can pass through breastmilk.




How can we best protect unborn and breastfed babies?









Kieskamp et al. approach








Kieskamp et al. approach


Converted to dose that would cause a baby to have the same level as the offspring – taking into effect half-life and breastfeeding duration











DHS recommendation for PFOA

Enforcement Standard

DHS recommendation for PFOA

Preventive action limit

of the enforcement standard


10%

PFOA has been
shown to cause
carcinogenic,
teratogenic, or
interactive effects

DHS recommends a combined enforcement standard of 20 ng/L for PFOA and PFOS.

PFOS

Perfluorooctane sulfonate



Available scientific information for PFOS:



Available scientific information for PFOA:



Lifetime health advisory 70 ng/L for PFOA and PFOS Established in 2016

Available scientific information for PFOS:



Oral reference dose 20 ng/kg-d Established for use in setting the lifetime health advisory

PFOS: Technical information ATSDR = Agency for Toxic Substances and Disease Registry

Available scientific

information for

Intermediate minimum risk level (MRL) 2 ng/kg-d Proposed by ATSDR in 2018 Exposure duration of 15 – 365 days

Available scientific information for PFOS:



State drinking water standard





Technical information




In 2016, EPA established a combined health advisory of 70 ng/L for PFOA and PFOS.

Babies are most sensitive to the effects of PFOS.




EPA based their advisory on a 2-generation study in rats.



Study selected was Luekber et al., 2005b

Key findings

mg/kg-d PFOS




Body weight (F0)

Reduced body weight in males and females at various timepoints during exposure - _____ corresponding with reduced food consumption

Summarized from Luebker et al., 2005b

Key findings


mg/kg-d PFOS



Summarized from Luebker et al., 2005b

Key findings

mg/kg-d PFOS



Body weight (F0)


Decreased weight per litter and reduced weight change per litter

Survival (F1)

Body weight (F1)


Key findings

mg/kg-d PFOS




Key findings

mg/kg-d PFOS



Summarized from Luebker et al., 2005b






We have learned more PFOS since 2016.



PFOS can cross the placenta during pregnancy.

PFOS can pass through breastmilk.








PFOS may increase the risk for asthma, food allergies, and certain infectious diseases.


In 2018, ATSDR proposed a minimum risk level of 2 ng/kg-d for PFOS.


ATSDR = Agency for Toxic Substances and Disease Registry












DHS recommends using ATSDR's minimum risk level for PFOS.


This approach protects from potential immune effects and infant exposure.



DHS' recommendation for PFOS

Enforcement Standard

DHS' recommendation for PFOS



Preventive action limit

PFOA has been shown to cause carcinogenic, teratogenic, or interactive effects DHS recommends a combined enforcement standard of 20 ng/L for PFOA and PFOS.

Thanks!

Sarah Yang, Ph.D. Groundwater Toxicologist Bureau of Environmental and Occupational Health Division of Public Health Wisconsin Department of Health Services


> <u>sarahp.yang@wi.gov</u> 608-266-9337

Additional information can be found on DHS' webpage: <u>dhs.wisconsin.gov\water\gws.htm</u>

The full scientific support document for all of the Cycle 10 compounds is available here: <u>dhs.wisconsin.gov\publications\p02434v.pdf</u>.

Additional information

LOAELs from non-acute studies



Data from Table 2-3 in ATSDR's Toxicological Profile for Perfluoroalkyls

Lau et al., 2006 results (part 1)

		Dose (mg/kg-d)					
Effects observe	Effects observed in mothers 1 3 5 10				20	40	
Body weight	Reduced maternal weight gain					\checkmark	\checkmark
	Increased percent of dams with full litter resorption			✓	✓	✓	✓
Reproduction	Reduced number of live fetuses					\checkmark	N/A
Reproduction	Increased percent of prenatal loss					✓	N/A
	Increased time to parturition		\checkmark		✓	\checkmark	N/A

Lau et al., 2006 results (part 2)

			Dose	(mg/	′kg-d)	
Effects observed i	in offspring	1	3	5	10	20
Survival	Reduced neonatal survival			\checkmark	\checkmark	\checkmark
Body weight	Reduced fetal body weight					\checkmark
Bone	Decreased number of ossification sites in					\checkmark
development	sternebrae, caudal vertebrae, metacarpals,					
·	metatarsals					
	Decreased number of ossification sites in	\checkmark	\checkmark		\checkmark	\checkmark
	forelimb proximal phalanges					
	Decreased number of ossification sites in	\checkmark			\checkmark	\checkmark
	hindlimb proximal phalanges					
	Reduced percent ossification in calvaria	\checkmark				\checkmark
	Reduced percent ossification in supraoccipital				\checkmark	\checkmark
	Reduced percent ossification in unossified hybrid					\checkmark
	Increased number of enlarged fontanel	\checkmark	\checkmark			\checkmark

Summary of epidemiological studies located during the literature review for PFOS

Category	Examples	Number of Studies
Metabolic	Diabetes (type 1, 2, and gestational), glucose tolerance, insulin resistance, BMI, obesity/overweight, adiposity, cholesterol, triglycerides	41
Birth outcomes	Birth size (weight, length, etc), gestation age, small for gestational age, ⁵ fetal growth, anogenital distance at birth	25
Neurological	Attention, impulse control, visual and spatial ability, cognitive development, executive function, autism spectrum disorder, intellectual disability	18
Reproductive	Endometriosis, preeclampsia, reproductive hormones, time to pregnancy, fertility, semen characteristics, pregnancy loss, menopause, puberty onset	13
Immune	Asthma, vaccine antibodies, allergic conditions, infectious disease incidence, atopic dermatitis	12
Thyroid	Thyroid hormones, thyroid function	10
Cardiovascular	heart attack, stroke, heart failure, arterial wall stiffness, coronary heart disease, blood pressure, hypertension	7
kidney	Chronic kidney disease, kidney function, glomerular filtration	7
Other	Vitamin D, bone density, lung function, dental carries, gut bacteria and metabolites, mortality,	6
DNA	Telomere length, DNA methylation	5
Liver	ALT (alanine aminotransferase), other liver function biomarkers	4
Cancer	Breast cancer	2

Lau et al., 2006 results (part 3)

			Dose	(mg/	kg-d)	
Effects observed i	n offspring	1	3	5	10	20
Dirth defects	Increased percent of tail defects	-		\checkmark	\checkmark	\checkmark
Birth defects	Increased percent of limb defects			\checkmark		\checkmark
Heart	Increased percent of microcardia				\checkmark	\checkmark
Development	Delayed eye opening			\checkmark	\checkmark	\checkmark
	Delayed vaginal opening		\checkmark			\checkmark
	Delayed first estrus			\checkmark		\checkmark
	Altered preputial separation	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark

Leubker et al., 2005 results (part 1)

		Dose (mg/kg-d)			(k
Effects observe	ed in F0 generation (males)	0.1	0.4	1.6	3.2
Body weight	Reduced body weight			√a	√ b
Food	Reduced food consumption days 1-42			\checkmark	\checkmark
consumption	Reduced food consumption days 56-63		\checkmark	\checkmark	\checkmark

- a. Days 56 through termination
- b. Days 36 through termination

Leubker et al., 2005 results (part 2)

		Do	se (m	ng/kg	-d)
Effects observe	d in F0 generation (females)	0.1	0.4	1.6	3.2
Body weight	Reduced body weight during precohabitation				√c
	Reduced body weight during gestation			√d	√e
	Reduced body weight during lactation		√f		√g
Food	Reduced food consumption during premating and gestation				\checkmark
consumption	Reduced food consumption during lactation			\checkmark	N/A
Reproduction	Reduced gestation duration				\checkmark
	Decreased implantation sites per delivered litter				\checkmark
	Increased percent of animals with stillborn pups				\checkmark
	Increased percent of animals with all pups dying (PND 1-4)				\checkmark

- c. Days 15-42
- d. Gestation days 3-10
- e. Gestation days 0-20Lactation day 7
- f. Lactation day 1; no results for days 4-21

Leubker et al., 2005 results (part 3)

		Dose (mg/kg-d)			
Effects obse	rved in F1 generation	0.1	0.4	1.6	3.2
Survival	Decreased liveborn				\checkmark
	Increased stillborn per litter				\checkmark
	Increased percent of pups found dead			√ g	√ h
	Reduced viability index			\checkmark	\checkmark
	Reduced lactation index			\checkmark	N/A
Body	Decreased weight per litter			√ i	√ j
weight	Reduced weight change per litter			√ k	N/A

g. Postnatal days 2-4 and 5-7

h. Postnatal day 1 and 2-4; not results for days 5-21

i. Postnatal days 1-21

j. Postnatal day 1; no results for days 2-21

k. Postnatal days 1-4; 4-7; 7-14; 14-21

Leubker et al., 2005 results (part 3)

		Dose (mg/kg-d)		
Effects observed in F2 generation 0.1		0.4		
Body weight	Reduced weight per litter		√ I	
	Reduced weight change per litter		√ m	

- I. Postnatal days 7 and 14
- m. Postnatal days 4-7 and 7-14